News
Curated oncology headlines from reputable sources, ranked by importance with Claude Opus 5.
News about: Myelodysplastic Syndromes (MDS) → cancer profile · × Clear filters
Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study
The phase 3 ENHANCE trial met neither of its dual primary endpoints: adding the anti-CD47 antibody magrolimab to azacitidine did not improve outcomes in 539 treatment-naive patients with intermediate- to very-high-risk myelodysplastic syndromes. The complete remission rate was 21.3% with magrolimab plus azacitidine versus 23.6% with placebo plus azacitidine, and median overall survival was 15.9 ve…
Blood cancer’s genetic warning signs may appear years early
Genetic warning signs of blood cancers that eventually progress may be detectable years before patients develop serious symptoms. The research could enable earlier clinical intervention and help clinicians distinguish true malignant clones from benign clonal hematopoiesis, a common age-related phenomenon. These findings have implications for monitoring strategies in patients with clonal hematopoie…
A 2026 update on myelodysplastic neoplasms: current state, challenges and future directions
A comprehensive review published in Nature Reviews Clinical Oncology provides a 2026 update on myelodysplastic neoplasms (MDS), a heterogeneous group of blood cancers characterized by ineffective blood cell production and a risk of progression to acute myeloid leukemia. The authors report that the epidemiological burden of MDS appears to be rising and detail recent advances in diagnosis, molecular…